Patterns, predictors, and patient-reported reasons for antidepressant discontinuation in the WHO World Mental Health Surveys.

antidepressants major depressive disorder medication discontinuation

Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
14 Sep 2023
Historique:
medline: 14 9 2023
pubmed: 14 9 2023
entrez: 14 9 2023
Statut: aheadofprint

Résumé

Despite their documented efficacy, substantial proportions of patients discontinue antidepressant medication (ADM) without a doctor's recommendation. The current report integrates data on patient-reported reasons into an investigation of patterns and predictors of ADM discontinuation. Face-to-face interviews with community samples from 13 countries ( 10.9% of 12-month ADM users reported discontinuation-based on recommendation of the prescriber while 15.7% discontinued in the absence of prescriber recommendation. The main patient-reported reason for discontinuation was feeling better (46.6%), which was reported by a higher proportion of patients who discontinued within the first 2 weeks of treatment than later. Perceived ineffectiveness (18.5%), predisposing factors (e.g. fear of dependence) (20.0%), and enabling factors (e.g. inability to afford treatment cost) (5.0%) were much less commonly reported reasons. Discontinuation in the absence of prescriber recommendation was associated with low country income level, being employed, and having above average personal income. Age, prior history of psychotropic medication use, and being prescribed treatment from a psychiatrist rather than from a general medical practitioner, in comparison, were associated with a lower probability of this type of discontinuation. However, these predictors varied substantially depending on patient-reported reasons for discontinuation. Dropping out early is not necessarily negative with almost half of individuals noting they felt better. The study underscores the diverse reasons given for dropping out and the need to evaluate how and whether dropping out influences short- or long-term functioning.

Sections du résumé

BACKGROUND BACKGROUND
Despite their documented efficacy, substantial proportions of patients discontinue antidepressant medication (ADM) without a doctor's recommendation. The current report integrates data on patient-reported reasons into an investigation of patterns and predictors of ADM discontinuation.
METHODS METHODS
Face-to-face interviews with community samples from 13 countries (
RESULTS RESULTS
10.9% of 12-month ADM users reported discontinuation-based on recommendation of the prescriber while 15.7% discontinued in the absence of prescriber recommendation. The main patient-reported reason for discontinuation was feeling better (46.6%), which was reported by a higher proportion of patients who discontinued within the first 2 weeks of treatment than later. Perceived ineffectiveness (18.5%), predisposing factors (e.g. fear of dependence) (20.0%), and enabling factors (e.g. inability to afford treatment cost) (5.0%) were much less commonly reported reasons. Discontinuation in the absence of prescriber recommendation was associated with low country income level, being employed, and having above average personal income. Age, prior history of psychotropic medication use, and being prescribed treatment from a psychiatrist rather than from a general medical practitioner, in comparison, were associated with a lower probability of this type of discontinuation. However, these predictors varied substantially depending on patient-reported reasons for discontinuation.
CONCLUSION CONCLUSIONS
Dropping out early is not necessarily negative with almost half of individuals noting they felt better. The study underscores the diverse reasons given for dropping out and the need to evaluate how and whether dropping out influences short- or long-term functioning.

Identifiants

pubmed: 37706298
doi: 10.1017/S0033291723002507
pii: S0033291723002507
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-12

Subventions

Organisme : NIDA NIH HHS
Pays : United States
Organisme : NIMH NIH HHS
ID : U01-MH60220
Pays : United States
Organisme : FIC NIH HHS
ID : FIRCA R03-TW006481
Pays : United States
Organisme : SAMHSA HHS
Pays : United States

Auteurs

Alan E Kazdin (AE)

Department of Psychology, Yale University, New Haven, CT, USA.

Meredith G Harris (MG)

School of Public Health, The University of Queensland, Herston, QLD 4006, Australia.
Queensland Centre for Mental Health Research, The Park Centre for Mental Health, QLD 4072, Australia.

Irving Hwang (I)

Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.

Nancy A Sampson (NA)

Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.

Dan J Stein (DJ)

Department of Psychiatry & Mental Health and South African Medical Council Research Unit on Risk and Resilience in Mental Disorders, University of Cape Town, Cape Town, South Africa.
Groote Schuur Hospital, Cape Town, South Africa.

Maria Carmen Viana (MC)

Department of Social Medicine, Postgraduate Program in Public Health, Federal University of Espírito Santo, Vitoria, Brazil.

Daniel V Vigo (DV)

Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.

Chi-Shin Wu (CS)

National Center for Geriatrics and Welfare Research, National Health Research Institutes, Zhunan Town, Taiwan.

Sergio Aguilar-Gaxiola (S)

Center for Reducing Health Disparities, UC Davis Health System, Sacramento, CA, USA.

Jordi Alonso (J)

Health Services Research Unit, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain.
Department of Medicine and Life Sciences, Pompeu Fabra University (UPF), Barcelona, Spain.
CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Corina Benjet (C)

National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico.

Ronny Bruffaerts (R)

Universitair Psychiatrisch Centrum - Katholieke Universiteit Leuven (UPC-KUL), Campus Gasthuisberg, Leuven, Belgium.

José Miguel Caldas-Almeida (JM)

Lisbon Institute of Global Mental Health and Comprehensive Health Research Centre, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal.

Graça Cardoso (G)

Lisbon Institute of Global Mental Health and Comprehensive Health Research Centre, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal.

Elisa Caselani (E)

Unit of Epidemiological and Evaluation Psychiatry, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.

Stephanie Chardoul (S)

Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, USA.

Alfredo Cía (A)

Anxiety Disorders Research Center, Buenos Aires, Argentina.

Peter de Jonge (P)

Department of Developmental Psychology, University of Groningen, Groningen, The Netherlands.
Interdisciplinary Center Psychopathology and Emotion Regulation, University Medical Center Groningen, Groningen, The Netherlands.

Oye Gureje (O)

Department of Psychiatry, University College Hospital, Ibadan, Nigeria.

Josep Maria Haro (JM)

Research, Teaching and Innovation Unit, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain.
Centre for Biomedical Research on Mental Health (CIBERSAM), Madrid, Spain.
Departament de Medicine, Universitat de Barcelona, Barcelona, Spain.

Elie G Karam (EG)

Department of Psychiatry and Clinical Psychology, Faculty of Medicine, Balamand University, Beirut, Lebanon.
Department of Psychiatry and Clinical Psychology, St George Hospital University Medical Center, Beirut, Lebanon.
Institute for Development Research Advocacy and Applied Care (IDRAAC), Beirut, Lebanon.

Viviane Kovess-Masfety (V)

Institut de Psychologie, EA 4057, Université Paris Cité, Paris, France.

Fernando Navarro-Mateu (F)

Unidad de Docencia, Investigación y Formación en Salud Mental (UDIF-SM), Gerencia Salud Mental, Servicio Murciano de Salud, Murcia, Spain.
Murcia Biomedical Research Institute (IMIB-Arrixaca), Murcia, Spain.
CIBER Epidemiology and Public Health-Murcia (CIBERESP-Murcia), Murcia, Spain.

Marina Piazza (M)

Instituto Nacional de Salud, Lima, Peru.
Universidad Cayetano Heredia, Lima, Peru.

José Posada-Villa (J)

Faculty of Social Sciences, Colegio Mayor de Cundinamarca University, Bogota, Colombia.

Kate M Scott (KM)

Department of Psychological Medicine, University of Otago, Dunedin, Otago, New Zealand.

Juan Carlos Stagnaro (JC)

Departamento de Psiquiatría y Salud Mental, Facultad de Medicina, Universidad de Buenos Aires, Argentina.

Margreet Ten Have (M)

Trimbos-Instituut, Netherlands Institute of Mental Health and Addiction, Utrecht, Netherlands.

Yolanda Torres (Y)

Center for Excellence on Research in Mental Health, CES University, Medellin, Colombia.

Cristian Vladescu (C)

National Institute for Health Services Management, Bucharest, Romania.

Ronald C Kessler (RC)

Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.

Classifications MeSH